Our commitment to scientific excellence is the basis for our ongoing clinical research. We are deeply appreciative of the study sites, investigators, patients, caregivers, and clinicians who support our efforts through their participation. Learn more about our trial data and currently enrolling trials below.
A Phase 3b, randomized, open-label, parallel-group, multicenter study to evaluate the efficacy and safety of two dosing regimens of ropeginterferon alfa-2b-njft.ClinicalTrials.gov: NCT05481151
A Phase 1/2, prospective, multicenter, open-label, dose-escalation trial to determine the safety, efficacy, and tolerability of ropeginterferon alfa-2b-njft in patients with PV, and define the maximum tolerated dose.
A Phase 3b, open-label extension trial in patients who completed PROUD-PV to assess the long-term efficacy of ropeginterferon alfa-2b-njft or standard first-line treatment (HU or other best available treatment*) in terms of disease response rate and changes in disease burden.
*Includes peginterferon alfa-2a, acetylsalicylic acid, anagrelide, IFN alfa, ruxolitinib, IFN alfa-2a, both ruxolitinib and IFN alfa-2a, ropeginterferon alfa-2b-njft, or both ropeginterferon alfa-2b-njft and IFN alfa-2a.
A Phase 3, randomized clinical trial conducted across 48 clinics in Europe to assess the noninferiority of ropeginterferon alfa-2b-njft versus hydroxyurea (HU) regarding disease response in the treatment of PV.
You are now leaving this site and being directed to a site not maintained by PharmaEssentia.
PharmaEssentia is not responsible for content or privacy policies on other sites.